OMERS ADMINISTRATION Corp Invests $470,000 in Personalis, Inc. (NASDAQ:PSNL)

OMERS ADMINISTRATION Corp purchased a new position in Personalis, Inc. (NASDAQ:PSNL - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 81,400 shares of the company's stock, valued at approximately $470,000. OMERS ADMINISTRATION Corp owned approximately 0.12% of Personalis at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Lightspeed Management Company L.L.C. acquired a new position in shares of Personalis in the 4th quarter worth approximately $47,169,000. abrdn plc bought a new stake in Personalis during the fourth quarter worth approximately $1,722,000. Dimensional Fund Advisors LP grew its position in Personalis by 144.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company's stock worth $2,372,000 after buying an additional 242,141 shares during the last quarter. Jane Street Group LLC grew its position in Personalis by 144.3% in the fourth quarter. Jane Street Group LLC now owns 401,314 shares of the company's stock worth $2,320,000 after buying an additional 237,033 shares during the last quarter. Finally, 683 Capital Management LLC bought a new position in shares of Personalis in the fourth quarter valued at $775,000. 61.91% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PSNL has been the subject of several research reports. HC Wainwright raised their price objective on Personalis from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $7.00 target price on shares of Personalis in a report on Thursday, April 10th. Guggenheim assumed coverage on Personalis in a research report on Thursday, May 15th. They issued a "buy" rating and a $6.00 price target for the company. Finally, Craig Hallum started coverage on Personalis in a report on Monday, March 17th. They set a "buy" rating and a $8.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $7.67.

Personalis Trading Down 2.1%

NASDAQ:PSNL traded down $0.10 during trading hours on Thursday, hitting $4.62. 434,228 shares of the stock traded hands, compared to its average volume of 1,009,295. The firm has a 50 day moving average price of $3.84 and a 200 day moving average price of $4.46. The firm has a market cap of $408.06 million, a price-to-earnings ratio of -2.75 and a beta of 1.83. Personalis, Inc. has a fifty-two week low of $1.14 and a fifty-two week high of $7.20.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The firm had revenue of $20.61 million during the quarter, compared to analyst estimates of $17.41 million. Research analysts predict that Personalis, Inc. will post -1.4 EPS for the current year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.